subscribe: Posts | Comments

What are birth control manufacturers hiding?

0 comments

Summary of story from Jezebel, December 6, 2011

Drug manufacturer Bayer AG withheld from the US regulators findings made by company researchers of increased reports of blood clots in users of its ‘Yasmin’ birth-control pills, according to the former head of the US Food and Drug Administration (FDA).

In a document presented in a federal court in Illinois, USA, David Kessler, the former FDA commissioner, said Bayer did not include an analysis “that demonstrated an increase in the US reporting rate” for venous thromboembolism, or clots, in a 2004 review of Yasmin’s safety sent to the agency.

However, Bayer is not the only birth-control manufacturer allegedly guilty of unethical or illegal practices.

Wyeth, now owned by Pfizer, have, allegedly, been illegally keeping a generic version of the antidepressant Effexor off the market.

It has also been accused of paying bribes for overseas business and sponsoring of unethical drug trials on victims of the 1984 Bhopal gas disaster.

Ortho-McNeil-Janssen, part of Johnson & Johnson, has been accused of hiding the risks of the Ortho-Evra birth-control patch, including a potentially higher risk of blood clots than that posed by birth control pills.

On top of that, it has allegedly paid kickbacks to pharmacy Omnicare to get more nursing home residents on its drugs.

Merck has allegedly made false statements about the safety of its widely-used pain medicine Vioxx, and marketed it for an unapproved use, for which the company is to pay a nearly $1 billion settlement.

And Merck was also accused of unethical behaviour by the US AIDS Healthcare Foundation recently.

The Foundation says that, with a severe crisis facing the nation’s AIDS Drug Assistance Program (ADAP), which has left 6,595 Americans in 12 states on waiting lists to receive lifesaving medications, Merck refuses to lower the price of its blockbuster HIV/AIDS drug, Isentress.

Isentress currently costs over $8,000 per patient per year for ADAP and is the most expensive first-line HIV/AIDS drug

Leave a Reply

Your email address will not be published. Required fields are marked *